NURO - Neurometrix gains on trial results of neurostimulation device Quell for fibromyalgia

Zerbor/iStock via Getty Images Shares of Neurometrix ([[NURO]] -0.8%) are up this morning as results of a trial of its neurostimulation device Quell were published in a scientific journal. After three months, patients who used a standard dose of neurostimulation using the Quell device saw reduced disease impact, pain, and functional impairment compared to a placebo group that received a low dose (sham) of neurostimulation, according to results published in the Journal of Pain Research. Earlier this month, Quell was granted Breakthrough Therapy designation from the FDA for fibromyalgia.

For further details see:

Neurometrix gains on trial results of neurostimulation device Quell for fibromyalgia